lisproinsulin (Humalog, Lispro, Admelog, HumaPenn Memoir, HumaPenn Luxura HD, Humalog U-200 KwikPen)
Jump to navigation
Jump to search
Introduction
Synthetic proinsulin with more rapid onset & shorter duration of action than regular insulin.
Humalog Mix 75/25:
Indications
* patients who have excessive blood glucose increases 1-2 hours after meals with hypoglycemia 4-5 hours later
Dosage
- injected 5-10 minutes before eating*
* May need to increase morning dose of NPH to compensate for loss of 'tail' or persistence of regular insulin action
Stable for 28 days refrigerated, 14 days at room temperature.
HumaPenn Memoir is a reusable pen $100, $45 with coupon lasts 3 years
HumaPenn Luxura HD measures Humalog in 1/2 units
Humalog U-200 is an option for patients using > 20 units/day of rapid-acting insulin[6]
Pharmacokinetics
- onset of action 15 minutes
- peak 45 minutes
- duration 3 hours[3]
Notes
- copy cat version of Humolog (Admelog) approved Dec 2017[7]
More general terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Prescriber's Letter 7(6):33 2000
- ↑ 3.0 3.1 Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
- ↑ Prescriber's Letter 14(4): 2007 Change in storage for Byetta and new insulin pens: HumaPen Memoir and HumaPen Luxura HD Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230408&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Deprecated Reference
- ↑ 6.0 6.1 Prescriber's Letter 22(8): 2015 (subscription needed) CHART: Comparison of Insulins and Injectable Diabetes Meds CHART: Tips to Improve Insulin Safety Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=310825&pb=PRL http://www.prescribersletter.com
- ↑ 7.0 7.1 Tucker ME First Humalog Copycat (Admelog) Approved by FDA. Medscape - Dec 11, 2017. https://www.medscape.com/viewarticle/889893
FDA News Release. December 11, 2017 FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588466.htm